Arcutis BiotherapeuticsvsThermo Fisher Scientific

ARQT and TMO stock compared: price, dividend, valuation and results, from SEC filings.

ARQT

Arcutis Biotherapeutics, Inc.

$27.19

Value $3.4B

-3.79%
ARQT's page

TMO

Thermo Fisher Scientific Inc

$694.92

Value $258B

-0.76%
TMO's page

Arcutis Biotherapeutics (ARQT) has a market value of $3.4B and Thermo Fisher Scientific (TMO) $258B. Over the last year, with dividends, ARQT moved +8.8% and TMO +20.5%. The P/E is 112.8 for ARQT and 36.5 for TMO. Dividend yield: ARQT none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARQT$3.4B

    TMO$258B

    TMO is 77 times ARQT

  • Revenue, 12 months

    ARQT$509M

    TMO$47.4B

    TMO is 93 times ARQT

  • Net income, 12 months

    ARQT$30M

    TMO$7.1B

    TMO is 236 times ARQT

  • Operating margin

    ARQT6.9%

    TMO17.9%

    11.0 points apart

  • ROIC

    ARQT9.0%

    TMO8.2%

    0.8 points apart

  • P/E

    ARQT112.8

    TMO36.5

    ARQT is 3.1 times TMO

  • Dividend yield

    ARQT0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    ARQT+34.3%

    TMO+11.5%

    22.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARQT+34.3%

TMO+11.5%

5010015020222023202420252026
Returns by period
PeriodARQTWith dividendsTMOWith dividends
1 year since November 14, 2025+8.8%Price +8.8%+20.5%Price +20.1%
3 years since November 16, 2023+1,294.4%+140.7% a yearPrice +1,294.4%+48.5%+14.1% a yearPrice +47.1%
5 years since November 15, 2021+34.3%+6.1% a yearPrice +34.3%+11.5%+2.2% a yearPrice +9.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARQTArcutis BiotherapeuticsTMOThermo Fisher Scientific

Valuation

ARQTTMO
Valuation
Price$27.19$694.92
Market value$3.4B$258B
Enterprise value (EV)–$293B
P/E112.836.5
P/E, 5-year median–32.7
P/B13.84.7
EV/EBIT–34.7
Free cash flow yield1.8%2.9%

Results and growth

ARQTTMO
Results and growth
Revenue, 12 months$509M$47.4B
Net income, 12 months$30M$7.1B
Free cash flow, 12 months$60M$7.6B
Earnings per share, 12 months$0.24$18.96
Revenue growth, year on year91.3%3.9%
Revenue growth a year, past–+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

ARQTTMO
Margins and returns on capital
Gross margin91.2%–
Operating margin6.9%17.9%
Net margin5.9%14.9%
ROIC9.0%8.2%
ROE14.9%13.4%

Balance sheet

ARQTTMO
Balance sheet
Cash$259M$6.1B
Total debt–$41.4B
Net debt / EBITDA–3.7
Interest cover2.6×5.5×

Dividends and buybacks

ARQTTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARQT or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Arcutis Biotherapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($258B) is about 76.5 times Arcutis Biotherapeutics ($3.4B), at today's prices.

How did ARQT and TMO stock do over the last 5 years?

Since November 15, 2021, ARQT's price moved +34.3% and TMO's +9.9%. With dividends: ARQT +34.3% (+6.1% a year), TMO +11.5% (+2.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARQT or TMO?

The dividend yield at today's price is none for Arcutis Biotherapeutics and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

What is the P/E of ARQT and TMO?

At today's price, the P/E is 112.8 for ARQT and 36.5 for TMO. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Arcutis Biotherapeutics or Thermo Fisher Scientific?

Over the last twelve months, the net margin was 5.9% for Arcutis Biotherapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin 6.9% and 17.9%. Revenue was $509M and $47.4B.

Which is the better investment, Arcutis Biotherapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.